- Topical composition containing an HMG-CoA reductase (statin) for the prophylaxis and treatment of fungal infections of the hair and/or skin.
- Topical formulation(s) are applied to the scalp and hair through serums, ointments, shampoos, sprays, or the like to prevent new or recurring infections.
- Additional products can be used to decontaminate objects or surfaces at home or at school to help prevent the spread or re-occurrence of infections.
Tinea capitis, a fungal infection of the scalp, has become widely integrated into metropolitan communities. Symptoms generally present as single or multiple patches of hair loss accompanied by inflammation, scaling, pustules, and itching. Current oral treatments have challenges such as compliance issues, liver toxicity, and/or interactions with other drugs. Importantly long-term follow-up of the children in our studies demonstrates that efficacy rates for existing oral antifungals are unacceptably low.
- In communities where tinea capitis is known to occur, prophylactic treatment can prevent or decrease the severity of the infection.
- Topical use of statin drugs and anti-fungal agents with well-understood safety profiles reduces the risk of liver toxicity or drug interactions
- Products for topical applications for prevention of new or recurring tinea capitis infections.
- Products for topical treatment of existing tinea capitis infections.
- Products to be applied to fomites such as bedsheets, hairbrushes, stuffed toys, or in the classroom, that carry the fungus and provide a means of re-infection.
Name: Marcia Molina
Phone: 785-341-8112 (mobile)